Home

Content about CDATA

February 25, 2013
The BIO CEO & Investor Conference

Recently BIO hosted the 15th annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. The conference is the largest investor conference focused on for established and emerging publicly traded and select private biotech companies.

BIO recently hosted the 15th annual BIO CEO & Investor Conference at the Waldorf Astoria New York, the largest investor conference focused on established and emerging publicly traded and select private biotech companies. This year’s event drew more than 1,200 industry leaders, welcomed over 750 investors and facilitated at least 1,300 One-on-One Partnering meetings. BIO’s successful portfolio of investor conferences includes the BIO Investor Forum taking place in San Francisco later this year.

February 1, 2013
Biotech in China

The biosimilars pathway is critical for China's biotechnology industry – and this is evident in the investment the government is making in the manufacture of biotech products

January 17, 2013
BIO Sponsorship Brings New Meaning to the Term “Double Helix”

BIO’s sponsorship opportunities provide industry leaders with heightened visibility through “Double Helix” and “Helix” sponsorships.

In molecular biology, the term double helix refers to the structure formed by double-stranded molecules of nucleic acids such as DNA and RNA. But here at BIO we know the term to also have a another meaning.

BIO recently launched a new sponsorship section on BIO.org that provides BIO’s Double Helix and Helix sponsors with a new information hub featuring upcoming branding and sponsorship opportunities, photos from past BIO events, and unique ways to get involved with BIO.

December 6, 2012
One-on-One Meetings and Business Development

As an exclusive members-only benefit, BIO offers complimentary One-on-One meeting rooms during the JP Morgan Healthcare Conference, taking place January 7-10, 2013, in San Francisco.

JP Morgan Healthcare Conference

July 19, 2012
Personalized Medicine and Diagnostics (PMDx) Working Group Mission Statement

The PMDxWorking Group endeavors to foster a positive public policy environment that maximizes the potential impact of the personalized medicine industry for the benefit of patients.

The PMDxWorking Group endeavors to foster a positive public policy environment that maximizes the potential impact of the personalized medicine industry for the benefit of patients. With a focus on improving legislative, intellectual property,regulatory, and reimbursement frameworks, the PMDxWorking Group seeks to better align the incentives connecting the research, development and commercialization of personalized medicine products.

June 27, 2012
Manager, Federal Government Relations

Department: Federal Government Relations 

Reports to: Senior Director, Federal Government Relations 

Primary Purpose of the Position:  

This position will help manage BIO’s federal government relations lobbying and research efforts related to biopharmaceutical issues including Medicare/Medicaid reimbursement, the FDA drug approval process, and implementation of health care reform. 

 Responsibilities:

June 19, 2012
Battelle/BIO State Bioscience Industry Development

At a time when the global economy struggles to recover from a severe recession and uncertainty remains regarding future economic growth, bioscience industry development is generating significant attention both globally and at home.

June 19, 2012
The Economic Contribution of University/Nonprofit Inventions in the United States: 1996-2010

Using an input output “I-O” approach to estimating the economic impact of academic licensing, and summing over the 15 years of available data for academic U.S. AUTM Survey respondents, the total contribution of these academic licensors to gross industry output ranges from $199B to $836B, in 2005 $US Dollars; contributions to GDP range from $86B to $388B, in 2005 $US Dollars.

Summary:

June 18, 2012
Taking Stock: How Global Biotechnology Benefits from Intellectual Property Rights

This report examines the role played by IPRs in both upstream and downstream phases of the research, development and commercialization of biotechnology products and provides a review and analysis of the existing body of knowledge concerning the role of IPRs.

Executive Summary

1) This report was commissioned by the Biotechnology Industry Organization (BIO).

2) This report examines the role played by IPRs in both upstream and downstream phases of the research, development and commercialization of biotechnology products and inventions in developed, emerging and developing economies.

3) The report provides a review and analysis of the existing body of knowledge concerning the role of IPRs more generally as well as specifically in biopharmaceutical and biotechnological innovation.

May 21, 2012
IFIC Survey Finds Consumers Support Current Food Labeling Policies

The International Food Information Council (IFIC) survey, “Consumer Perceptions of Food Technology & Sustainability”, shows U.S. consumers overwhelmingly support current federal rules for labeling foods. 

SUMMARY
The International Food Information Council (IFIC) survey, “Consumer Perceptions of Food Technology & Sustainability”, shows U.S. consumers overwhelmingly support current federal rules for labeling foods. Of the small percentage of consumers who want more detail on their labels, only 3 percent (or 1 percent of the total sample) cited biotechnology as an information need on the label.
 
May 18, 2012
Biotechnology’s Impact on Food Ingredients

Natural biological processes have been employed for food production for more than 8,000 years. Bread, cheese, yogurt, beer and wine, vinegar, and many other foods are produced through microbial fermentation or enzymatic activity.

Biotechnology’s Impact on Food Ingredients

April 18, 2012
Ag Biotech: An Environmental Success Story

Biotech allows us to meet the food production demands of a growing population in an economical way while lessening environmental impact. 

Farmers have adopted biotechnology since 1996 because biotech crops grow healthier plants that yield more per acre with reduced production costs. But planting biotech crops also helps to enhance soil, air and water quality. Biotech allows us to meet the food production demands of a growing population in an economical way while lessening environmental impact. 

February 21, 2012
Value Drivers Under the Influence—How Licensing and Key Events Affect Valuation

Panelists at the CEO & Investor Conference discuss the state-of-play on valuation for emerging biotech companies

The 14th Annual BIO CEO & Investor Conferenceplenary session – Value Drivers Under the Influence – started on a high note, with Michael Margolis, RPh, Managing Director of Healthcare Investment Banking at ROTH Capital Partnerspointing out that ‘we’re seeing the markets open up right now with lots of pharmaceutical and biotech activity.’

February 3, 2012
BIO Comments on US EU Dialogue

 

February3, 2012

 

L. Daniel Mullaney

Assistant U.S. TradeRepresentative for Europeand the MiddleEast

Officeof theU.S. TradeRepresentative

600 17th Street NW Washington, DC 20508

Re: U.S.-EU HighLevel Working GrouponJobs andGrowth

February 1, 2012
Consumer Products Made with Industrial Biotechnology

Check out all of the everyday products you use that are now made from industrial biotechnology processes, which benefit you and reduce impact on the environment.

January 25, 2012
BIO Media Briefing Highlights 2012 Policy Priorities

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, hosted a media briefing on January 23 to share BIO’s advocacy accomplishments in 2011 and policy priorities for 2012.

January 15, 2012
About BIO's Industrial & Environmental Section

Industrial & Environmental — Develops biotechnology industry policy on environmental and industrial biotechnology issues, promotes the use of industrial enzymes, conversion of biomass to energy and chemicals, and innovative clean up technologies.

Facts

Description 

December 31, 2011
Timeline: 8,000 Years of Mankind

Harnessing microbes to change the world, one process at a time.

6000 B.C. — Ancient writings from around 6000 B.C. indicate the Sumerians and Babylonians knew how to use microbial yeasts to make beer.

4000 B.C. — The Egyptians make leavened bread using yeast.

500 B.C. — The Chinese use filamentous fungi (mold) as an antibiotic to treat boils.

mid-1800’s — Louis Pasteur proposes that fermentation is a result of microbial activity.

December 13, 2011
BIO One-on-One Partnering

The biotechnology and pharmaceutical industries are continuously trying to improve efficiency in access to industry knowledge, innovation, and therapies.

The biotechnology and pharmaceutical industries are continuously trying to improve efficiency in access to industry knowledge, innovation, and therapies.  Partnering is the technological solution to this problem.  In a resource constrained environment, BIO One-on-One Partnering exists to ensure that companies of all shapes and sizes are able to have better and more meaningful access to potential partners from all over the globe.  This leads to a more productive conference experience, and BIO is proud to be a leader in the partnering field.

December 1, 2011
Capital Formation Spurs Job Growth

Congress has the opportunity to help speed lifesaving cures and treatments to patients by removing burdens to innovation in our industry.

Today, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of implementing policies that will spur job growth through capital formation while protecting investors.

Congress has the opportunity to help speed lifesaving cures and treatments to patients by removing burdens to innovation in our industry.

November 11, 2011
Therapeutic Discovery Project: 7 Companies, 1 Year Later

The Therapeutic Discovery Project provided much-needed relief for emerging biotech companies  working on life-saving treatments and cures

Each day in labs across the country, biotech researchers uncover scientific discoveries that could lead to the next medical breakthrough that provides a treatment or cure for a debilitating and devastating disease, such as cancers, mental illnesses, heart disease and Parkinson’s disease.

November 10, 2011
Session Submission Update: Where Are We Now?

With the overwhelming success of our recent Call for Sessions, next year’s BIO International Convention may be the best yet!

With the overwhelming success of our recent Call for Sessions, next year’s BIO International Convention may be the best yet!

Companies, institutions, and organizations from around the globesubmitted more than 500 entries to host a session at the Convention. Word has quickly spread that for an organization to maximize visibility and credibility among the most influential people in the industry, becoming a session host is invaluable.

November 8, 2011
Top 5 Reasons Why SBIR Must be Reauthorized Now

The Small Business Innovation Research Grants Program Provides Critical Support to Small Biotech Companies Working on Promising Innovations

Small Business Innovation Research (SBIR) grants are critical for supporting small biotech companies with promising science to continue critical research and development of treatments and cures for debilitating and life threatening diseases such as HIV/AIDS, cancer, Multiple Sclerosis and Parkinson’s.

November 3, 2011
FY2011 Innovative Treatment Approvals

BIO President and CEO Jim Greenwood congratulated the FDA and biopharmaceutical sponsors for making 35 novel new treatments available to patients in FY11.

BIO President and CEO Jim Greenwood congratulated the U.S. Food and Drug Administration (FDA) and biopharmaceutical sponsors for making 35 novel new treatments available to patients in FY11, including breakthrough therapies for lupus, hepatitis C, rare diseases, and devastating cancers. These advancements in patient care represent the leading edge of the next generation of biotechnology innovations.

October 19, 2011
The Power of Partnering, Expanded

Where can you network and partner with 15,000+ industry leaders from 65 countries across the globe?

Where can you network and partner with 15,000+ industry leaders from 65 countries across the globe?

The 2012 BIO International Convention, June 18-21, in Boston, Mass. is the global marketplace where you can stay on the forefront of biotech's most important developments through our education, BIO Exhibiton, networking events, and the BIO Business Forum powered by BIO One-on-One Partnering.